About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker RIGL · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 6, 2026Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
NCT05308264 · Low Risk Myelodysplastic Syndromes
R906289 Monosodium (R289 Na)
RIGL
Rigel Pharmaceuticals
Phase 1/2Recruiting86Dec 2027Registry ↗
Sep 1, 2026Study of Olutasidenib and Temozolomide in HGG
NCT06161974 · High Grade Glioma, Astrocytoma
Olutasidenib + TMZ
RIGL
Rigel Pharmaceuticals
Phase 2Recruiting60Jun 2029Registry ↗
Aug 11, 2026Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
NCT07486713 · AML (Acute Myeloid Leukemia), Glioma
Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3…
RIGL
Rigel Pharmaceuticals
Phase 4Recruiting16Apr 30, 2027Registry ↗
Aug 10, 2026Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
NCT07704658 · NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer
Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hor…
RIGL
Rigel Pharmaceuticals
Phase 4Recruiting12Jul 30, 2027Registry ↗
Mar 15, 2024Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocyt…
NCT04904276 · ITP, Immune Thrombocytopenia
Fostamatinib
RIGL
Rigel Pharmaceuticals
—Terminated16Nov 17, 2022Registry ↗
Dec 11, 2023Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (IT…
NCT02077192 · Immune Thrombocytopenic Purpura
Fostamatinib Disodium
RIGL
Rigel Pharmaceuticals
Phase 3Completed123Jun 2, 2020Registry ↗
Aug 18, 2023Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy a…
NCT04629703 · Covid19, SARS (Severe Acute Respiratory Syndrome)
Fostamatinib, Placebo
RIGL
Rigel Pharmaceuticals
Phase 3Completed280Sep 5, 2022Registry ↗
May 25, 2023A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodi…
NCT03764618 · Warm Antibody Autoimmune Hemolytic Anemia
Fostamatinib disodium, Placebo
RIGL
Rigel Pharmaceuticals
Phase 3Completed90Apr 11, 2022Registry ↗
Mar 17, 2022A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Aut…
NCT04138927 · Warm Antibody Autoimmune Hemolytic Anemia
Fostamatinib disodium
RIGL
Rigel Pharmaceuticals
Phase 3Enrolling by invitation90Apr 2024Registry ↗
Jul 21, 2021A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemi…
NCT02612558 · Warm Antibody Autoimmune Hemolytic Anemia
Fostamatinib 150 mg bid
RIGL
Rigel Pharmaceuticals
Phase 2Completed26Dec 2019Registry ↗
Jun 27, 2019Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
NCT02112838 · IGA Nephropathy
Fostamatinib 150 mg, Fostamatinib 100 mg
RIGL
Rigel Pharmaceuticals
Phase 2Completed76Mar 23, 2018Registry ↗
Feb 12, 2019A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopen…
NCT02076399 · Immune Thrombocytopenic Purpura
Fostamatinib disodium, Placebo
RIGL
Rigel Pharmaceuticals
Phase 3Completed76Apr 21, 2016Registry ↗
Jan 25, 2019A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocy…
NCT02076412 · Immune Thrombocytopenic Purpura
Fostamatinib Disodium, Placebo
RIGL
Rigel Pharmaceuticals
Phase 3Completed74Aug 2016Registry ↗
Aug 1, 2018Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP
NCT03363334 · Immune Thrombocytopenic Purpura
Fostamatinib disodium 100 mg, Fostamatinib disodium 150 mg
RIGL
Rigel Pharmaceuticals
—No longer available——Registry ↗
May 1, 2017Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)
NCT00665626 · Rheumatoid Arthritis
Fostamatinib disodium (R935788), Placebo
RIGL
Rigel Pharmaceuticals
Phase 2Completed219Jun 2009Registry ↗
Oct 10, 2016Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Diseas…
NCT02040623 · Chronic Graft-versus-host Disease
R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0…
RIGL
Rigel Pharmaceuticals
Phase 2Completed35Jul 2016Registry ↗
Oct 3, 2016To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctiv…
NCT01900249 · Keratoconjunctivitis Sicca
R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0…
RIGL
Rigel Pharmaceuticals
Phase 2Completed204Jul 2014Registry ↗
Sep 29, 2016A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
NCT01591044 · Asthma
Placebo, R940343 1mg
RIGL
Rigel Pharmaceuticals
Phase 2Completed301Jul 2013Registry ↗
Sep 19, 2016Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
NCT00798096 · T Cell Lymphoma
Fostamatinib Disodium
RIGL
Rigel Pharmaceuticals
Phase 2Completed18Apr 2010Registry ↗
Sep 19, 2016Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma
NCT00446095 · Lymphoma
fostamatinib
RIGL
Rigel Pharmaceuticals
Phase 1/2Completed81Apr 2010Registry ↗
Sep 16, 2016Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis
NCT00665925 · Rheumatoid Arthritis
Fostamatinib disodium (R935788), Fostamatinib disodium (R93…
RIGL
Rigel Pharmaceuticals
Phase 2Completed457Jun 2009Registry ↗
Jul 14, 2016Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic…
NCT01597050 · Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
R932333, Placebo
RIGL
Rigel Pharmaceuticals
Phase 2Completed54Sep 2013Registry ↗
Jun 3, 2016Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocy…
NCT00706342 · Purpura, Thrombocytopenic, Idiopathic
Fostamatinib Disodium / R935788
RIGL
Rigel Pharmaceuticals
Phase 2Completed18Apr 2010Registry ↗
Oct 23, 2015Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
NCT02433236 · IGA Nephropathy
Fostamatinib Disodium tablet 100 mg, Fostamatinib Disodium…
RIGL
Rigel Pharmaceuticals
Phase 2Withdrawn0Sep 2015Registry ↗

24 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:49 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances